Read time: 3 minutes.
Throughout 2024 we published blogs sharing scientific meeting recaps, educational content, personal stories, treatment news, and so much more. Below are the most popular articles we published in 2024.
If you’re looking for survivor features and personal stories, you can see all the lung cancer survivors we highlighted in 2024 right here.
2024 ASCO: Highlights of Lung Cancer Research
In June, we recapped the annual American Society of Clinical Oncology meeting. Thousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates (including LUNGevity staff) met to discuss lifesaving cancer research.
Lung Cancer Masterclass: Get Smart About Lung Cancer
As lung cancer treatments get more specialized and advanced, it means there's much to learn about different treatment options, how they work, and who they’re for. The Lung Cancer Masterclass brings together videos by lung cancer experts on the topics of:
- Surgery
- Radiation
- Chemotherapy
- Targeted Therapies
- Clinical Trials
Leveraging Genetics to Understand Why Younger Adults Are Developing Lung Cancer
Earlier this year we caught up with one of our research grant awardees, Jaclyn LoPiccolo, PhD, MD, attending physician at the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute. Dr. LoPiccolo was awarded a 2023 LUNGevity Career Development Award for her research that’s investigating why people in their 20s and 30s are being diagnosed with lung cancer.
How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
This is the final article in a 3-part series on how drugs get tested and approved for lung cancer. Part three focuses on the stages of FDA review and explains how drugs typically get approved—as well as how drugs get fast-tracked—as is common among lung cancer treatments. You will find links to the previous two parts in the article as well.
Kicking Drug Resistance to the Curb in RET-positive Lung Cancer
While targeted therapies are a common treatment for RET-positive lung cancer and can work well, the tumors eventually become resistant to the treatment and begin to grow again. Why this happens is a very important question, and Tejas Patil, MD, assistant professor of hematology and oncology at the University of Colorado, Denver, is using a LUNGevity research award to help answer it.